跳转至内容
Merck
CN

U1128

尿嘧啶

BioReagent, suitable for cell culture

别名:

2,4(1H,3H)-嘧啶二酮, 2,4-二羟基嘧啶, 灭胞素

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C4H4N2O2
化学文摘社编号:
分子量:
112.09
UNSPSC Code:
12352207
NACRES:
NA.75
PubChem Substance ID:
EC Number:
200-621-9
Beilstein/REAXYS Number:
507828
MDL number:
Assay:
≥99% (HPLC)
Biological source:
synthetic (organic)
Form:
powder
Solubility:
1 M NaOH: 50 mg/mL, clear to slightly hazy, colorless to faintly yellow
Storage temp.:
room temp
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

synthetic (organic)

Quality Level

product line

BioReagent

assay

≥99% (HPLC)

form

powder

technique(s)

cell culture | mammalian: suitable

mp

>300 °C (lit.)

solubility

1 M NaOH: 50 mg/mL, clear to slightly hazy, colorless to faintly yellow

storage temp.

room temp

SMILES string

O=C1NC=CC(=O)N1

InChI

1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)

InChI key

ISAKRJDGNUQOIC-UHFFFAOYSA-N

General description

尿嘧啶属于嘧啶碱基家族。它是天然存在的,是RNA重要而活跃的一部分。

Application

尿嘧啶已用作完全合成培养基1×、合成完全葡萄糖基酵母培养基(SC)和酵母提取物(YES)培养基的补充物,用于培养酵母细胞。

Biochem/physiol Actions

尿嘧啶及其衍生物在合成癌症、病毒感染、常染色体隐性遗传病、甲状腺和糖尿病药物的药物化学中不可或缺。


Still not finding the right product?

Explore all of our products under 尿嘧啶


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Sandra M Carvalho et al.
PloS one, 8(3), e58492-e58492 (2013-03-19)
Links between carbohydrate metabolism and virulence in Streptococcus pneumoniae have been recurrently established. To investigate these links further we developed a chemically defined medium (CDM) and standardized growth conditions that allowed for high growth yields of the related pneumococcal strains
William B White et al.
The New England journal of medicine, 369(14), 1327-1335 (2013-09-03)
To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new
Brian T Wilhelm et al.
Nature protocols, 5(2), 255-266 (2010-02-06)
Next-generation sequencing technologies are revolutionizing genomics research. It is now possible to generate gigabase pairs of DNA sequence within a week without time-consuming cloning or massive infrastructure. This technology has recently been applied to the development of 'RNA-seq' techniques for



全球贸易项目编号

货号GTIN
U1128-25G04061837404122
U1128-100G04061837404108